M
Mario Colucci
Researcher at University of Bari
Publications - 151
Citations - 5320
Mario Colucci is an academic researcher from University of Bari. The author has contributed to research in topics: Fibrinolysis & Plasminogen activator. The author has an hindex of 36, co-authored 150 publications receiving 5026 citations. Previous affiliations of Mario Colucci include University of Washington & University of Perugia.
Papers
More filters
Journal ArticleDOI
Cultured human endothelial cells generate tissue factor in response to endotoxin.
Mario Colucci,Giovanna Balconi,Roberto Lorenzet,Attilio Pietra,D Locati,Maria Benedetta Donati,Nicola Semeraro +6 more
TL;DR: These endotoxin effects were observed in the absence of endothelial damage, as shown by phase-contrast microscopy and lack of 51Cr release, and could contribute to elucidate the pathogenesis of vascular complications associated with endotoxemia in man.
Journal ArticleDOI
Generation in Plasma of a Fast-acting Inhibitor of Plasminogen Activator in Response to Endotoxin Stimulation
TL;DR: The marked increase in the level of PA-inhibitor in blood may contribute to the pathogenesis of DIC in septicemia and a very strong correlation was found between inhibition of t-PA and of urokinase in all conditions, suggesting that this fast-acting inhibitor reacts with both plasminogen activators.
Journal ArticleDOI
Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
TL;DR: Etude chez 118 malades atteints d'angor et presentant a l'angiographie des images de stenose coronarienne, significative de l'inhibiteur d'activateur de plasminogene en correlation avec l'activite fibrinolytique globale.
Journal ArticleDOI
Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.
Yves Vanrenterghem,Leo Roels,T. Lerut,Jacques Gruwez,Paul Michielsen,Paolo Gresele,Hans Deckmyn,Mario Colucci,Jozef Arnout,Jozef Vermylen +9 more
TL;DR: In this paper, the incidence of thromboembolic complications was compared retrospectively in 90 cadaveric kidney allograft recipients treated with cyclosporin and low-dose steroids and the same number of CKG recipient treated with azathioprine, antilymphocyte globulin, and high-dose steroid.
Journal ArticleDOI
Sepsis, thrombosis and organ dysfunction.
TL;DR: New insights into the pathogenesis of DIC and MODS may have implications for the development of new therapeutic agents potentially useful for the management of severe sepsis.